March 11, 2022, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko” hereafter) today announced that it had declared two next-generation precision oncology drug candidates. Both candidates were independently discovered from the Abbisko proprietary small molecule discovery platform and have entered the IND-enabling stage. 

PCC nomination for ABSK112, a next-generation EGFR-exon20 inhibitor with significantly improved selectivity and brain penetrating ability, for EGFR-driven lung cancer.

PCC nomination for ABSK071, a next-generation KRas-G12C inhibitor with significantly improved potency and drug-like properties, for multiple types of cancer driven by KRas-G12C.

In addition, Abbisko will present several latest preclinical and translational research results at the American Association of Cancer Research (AACR) Annual Meeting 2022 in New Orleans, United States, from April 8 to 13. The presented data will highlight our clinical programs of ABSK021, ABSK043, and preclinical program of ABSK111:

Title: A potent and selective small molecule antagonist of PD-L1 ABSK043 demonstrates significant anti-tumor efficacy in combination with other agents in preclinical models

Session Category: Immunology

Session Title: Preclinical Immunotherapy 

Permanent Abstract Number: LB530

Title: Discovery and characterization of ABSK111, a selective, CNS-penetrable, and broad-spectrum EGFR inhibitor targeting exon20 insertion, atypical and extracellular mutations

Session Category: Experimental and Molecular Therapeutics

Session Title: Small Molecule Therapeutic Agents

Permanent Abstract Number: LB525

Title: In vivo efficacy screen of a CSF-1R inhibitor ABSK021 in mouse syngeneic tumor models reveals immune features that may predict its therapeutic response

Session Category: Clinical Research Excluding Trials

Session Title:  Biomarkers

Permanent Abstract Number: LB513

The AACR Annual Meeting is one of the oldest and largest academic conferences for cancer research in the world. It covers the latest discoveries across the spectrum of cancer research—from population science and prevention, to cancer biology, translational, and clinical studies and to survivorship and advocacy—and highlights the work of the best minds in research and medicine from institutions around the world.